Behavioral Wire

@behavioralwire

Mental health industry intelligence covering markets, regulation, research, cannabis, psychedelics, pharma, and digital health.

United States

Pinned
Behavioral Wire
@behavioralwire
Aug 14
FOLLOW US Behavioral health markets, trials, policy, and signals. Coverage Pharma / Psychedelics / Cannabis Digital Health / Regulation / Research What moved. Why it matters. What to watch next.
Behavioral Wire
From behavioralwire.com
Behavioral Wire
@behavioralwire
12h
A Johns Hopkins team coded 600 public comments from the five most-commented FDA reviews of 2020 to 2024: 90.2% supported approval. The study's own appendix of 44 advisory committee reviews shows comment volume tracking committee votes in no consistent way. In the five cases,
1
Behavioral Wire
@behavioralwire
18h
Thank you @JackGorsline. We appreciate it.
Jack Gorsline
@JackGorsline
20h
Big ups to Behavioral Wire (@behavioralwire) for breaking the Compass Pathways NDA filing news first this morning. New kids on the block already breaking big news. Give them a follow!
1
Behavioral Wire
@behavioralwire
23h
Compass Pathways has completed its New Drug Application to the FDA for COMP360 psilocybin in treatment-resistant depression. The submission is supported by two Phase 3 trials and a Phase 2b study that each met their primary endpoint, with more than 1,000 participants in total.
Behavioral Wire
@behavioralwire
Nov 6
Medicare's final 2027 physician fee schedule raises psychiatric collaborative care well above July's proposal.
1

Behavioral Wire’s posts